Terumo India in partnership with Sensible Medical Innovations

The partnership will grant exclusive distribution rights for ReDS Pro and knowledge-sharing of ReDS technology in India

Terumo India, the Indian arm of Terumo Corporation, a global leader in medical technology, announced that it has signed a partnership with Sensible Medical Innovations, the market leader in medical radar monitoring and imaging technology (ReDS), that grants it exclusive distribution rights for ReDS Pro and knowledge-sharing of ReDS technology in India. 


ReDS Pro is used to measure the absolute lung fluid volume in patients, which has strong correlation with symptoms of Coronary Heart Failure (CHF). It is a non-invasive method that takes only 45 seconds to measure. Lung fluid assessment with ReDS Pro is proven to be as accurate as that measured by a CT scan. Periodic monitoring through ReDS™ Pro and titration of medicines in heart failure patients can potentially reduce hospitalization rates by 30 per cent. ReDS technology has been adapted for medical use from an Israeli military application where it was used to see through walls.

Making the announcement, Shishir Agarwal, MD, Terumo India, said, “We are delighted to introduce ReDS Pro, which represents the gold standard for monitoring and managing heart failure patients, to Indian healthcare. We look forward to working with Sensible Medical in bringing the ReDS Pro device to every hospital in India to support them in managing their patients more effectively.”

Amir Ronen, CEO, Sensible Medical, said, “There is a severe need for a reliable tool to assess and monitor pulmonary congestion, which is paramount to guide heart failure treatment. We are excited to work together with Terumo India in this new long-term partnership, to make ReDS Pro available in India and improve patient care.”

ReDS technology is the first accurate, absolute and actionable tool for periodic assessment of pulmonary congestion monitoring and guide management. It has been proven to reduce re-admissions in various clinical studies and is used in over 100 care centers around the world.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button